KALA BIO, Inc. (KALA) Form 8-K — Nov 9, 2026
KALA BIO announced preliminary unaudited Q3 2026 results, with net loss of approximately $0.8 million versus $7.6 million in the year-ago quarter, a roughly 90% reduction in quarterly burn. For the nine months ended September 30, 2026, net loss was approximately $4.0 million compared to $27.7 million in the same period of 2025. The company held approximately $7.0 million in cash, cash equivalents and short-term investments with no debt. CEO Avi Minkowitz credited cost reduction and ongoing strategic initiatives, while the company continues pivoting toward an on-premises AI infrastructure business built around the licensed Researgency platform alongside its MSC-S biologics pipeline.
Key figures
- Net Income
- -$0.8 million (Q3 2026 net loss)
- Cash Position
- 7000000
- Total Debt
- no debt
- Prior year q3 net loss
- $7.6 million
- Nine month 2025 net loss
- $27.7 million
- Nine month 2026 net loss
- ~$4.0 million
- Quarterly loss reduction yoy
- ~90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.